Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition

Neoplasia (United States)

Volumn 15, Issue 6, 2013, Pages 620-630

  Coppock, Joseph D ^a   Wieking, Bryant G ^a   Molinolo, Alfredo A ^b   Gutkind, J Silvio ^b   Keith Miskimins, W ^a   Lee, John H ^a  

^a SANFORD RESEARCH   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; INITIATION FACTOR 4E BINDING PROTEIN 1; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CELL METABOLISM; CELL PROLIFERATION; CELLULAR IMMUNITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE ESCALATION; FLOW CYTOMETRY; HEAD AND NECK CANCER; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; VIRAL CLEARANCE; WART VIRUS; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 84878648179     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13432     Document Type: Article

References (55)

1. American Cancer Society (2011). Cancer Facts & Figures 2011. American Cancer Society, Atlanta, GA.
2. Marklund L and Hammarstedt L (2011). Impact of HPV in oropharyngeal cancer. J Oncol 2011, 509036.
3. Dufour X, Beby-Defaux A, Agius G, and Lacau St Guily J (2012). HPV and head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 129, 26-31.
4. Gillison M, Kahle L, Graubard BI, and Chaturvedi AK (2012). Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 307, 699-703.
5. Marur S, D'Souza G, Westra WH, and Forastiere A (2010). HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11, 781-789.
6. Lee DW, Anderson ME, Wu S, and Lee JH (2008). Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer. Arch Otolaryngol Head Neck Surg 134, 1316-1323.
7. Hoover AC, Spanos WC, Harris GF, Mary E, Klingelhutz AJ, and Lee JH (2007). The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck Surg 133, 495-502.
8. Schlecht NF, Burk RD, Adrien L, Dunne A, Kawachi N, Sarta C, Chen Q, Brandwein-Gensler M, Prystowsky MB, Childs G, et al. (2007). Gene expression profiles in HPV-infected head and neck cancer. J Pathol 213, 283-293.
9. Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, Anderson ME, and Lee JH (2009). Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 135, 1137-1146.
10. Mazurek S (2011). Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43, 969-980.
11. Mazurek S, Zwerschke W, Jansen-Durr P, and Eigenbrodt E (2001). Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 356, 247-256.
12. Leemans CR, Braakhuis BJM, and Brakenhoff RH (2011). The molecular biology of head and neck cancer. Nat Rev Cancer 11, 9-22.
13. Noch E and Khalili K (2012). Oncogenic viruses and tumor glucose metabolism: like kids in a candy store. Mol Cancer Ther 11, 14-23.
14. Spangle JM and Münger K (2010). The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol 84, 9398-9407.
15. Liao Y-M, Kim C, and Yen Y (2011). Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol 3, 22.
16. Hu M, Ekshyyan O, Herman Ferdinandez L, Rong X, Caldito G, and Nathan C-AO (2011). Efficacy and comparative effectiveness of sirolimus as an anticancer drug. Laryngoscope 121, 978-982.
17. Molinolo A, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, et al. (2007). Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13, 4964-4973.
18. Tennant DA (2011). PK-M2 makes cells sweeter on HIF1. Cell 145, 647-649.
19. Luo W and Semenza GL (2011). Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2, 551-556.
20. Amornphimoltham P, Leelahavanichkul K, Molinolo A, Patel V, and Gutkind JS (2008). Inhibition of mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions. Clin Cancer Res 14, 8094-8101.
21. Raimondi AR, Molinolo A, and Gutkind JS (2009). Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 69, 4159-4166.
22. Czerninski R, Amornphimoltham P, Patel V, Molinolo A, and Gutkind JS (2009). Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila) 2, 27-36.
23. Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, and Gutkind JS (2008). A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res 68, 1144-1153.
24. Patel V, Marsh CA, Dorsam RT, Mikelis CM, Masedunskas A, Amornphimoltham P, Nathan CA, Singh B, Weigert R, Molinolo AA, et al. (2011). Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 71, 7103-7112.
25. Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, and Lee JH (2009). Preclinical models of HPV+ and HPV-HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck 31, 911-918.
26. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A, and Kreutz M (2006). Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013-2021.
27. Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T, and Inoue N (2008). Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol 180, 7175-7183.
28. Goetze K, Walenta S, Ksiazkiewicz M, Kunz-Schughart LA, and Mueller-Klieser W (2011). Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol 39, 453-463.
29. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, et al. (2007). Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812-3819.
30. Amiel E, Everts B, Freitas TC, King IL, Curtis JD, Pearce EL, and Pearce EJ (2012). Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol 189, 2151-2158.
31. Srivastava RK, Utley A, and Shrikant PA (2012). Rapamycin: a rheostat for CD8+ T-cell-mediated tumor therapy. Oncoimmunology 1, 1189-1190.
32. Hoover AC, Strand GL, Nowicki PN, Anderson ME, Vermeer PD, Klingelhutz AJ, Bossler AD, Pottala JV, Hendriks W, and Lee JH (2009). Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 28, 3960-3970.
33. Brenner JC, Graham MP, Kumar B, Lindsay M, Kupfer R, Lyons RH, Bradford CR, and Carey TE (2010). Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 32, 417-426.
34. Broggini-Tenzer A, Vuong V, and Pruschy M (2011). Metabolism of tumors under treatment: mapping of metabolites with quantitative bioluminescence. Radiother Oncol 99, 398-403.
35. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, and Gutkind JS (2005). Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65, 9953-9961.
36. Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo A, Mitchell JB, and Gutkind JS (2012). mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 11, 401-414.
37. Lill C, Kornek G, Bachtiary B, Selzer E, Schopper C, Mittlboeck M, Burian M, Wrba F, and Thurnher D (2011). Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced. Wien Klin Wochenschr 123, 215-221.
38. Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Kai Siung Chang J, Ampil F, Glass J, and Nathan C-AO (2009). Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 8, 2255-2265.
39. Molinolo A, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt SM, Patel V, Seiwert TY, and Gutkind JS (2012). mTOR as a molecular target in HPVassociated oral and cervical squamous carcinomas. Clin Cancer Res 18, 2558-2568.
40. Koukourakis MI, Giatromanolaki A, Winter S, Leek R, Sivridis E, and Harris AL (2009). Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology 77, 285-292.
41. Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, and Mueller-Klieser W (2006). Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 81, 130-135.
42. Walenta S, Schroeder T, and Mueller-Klieser W (2004). Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 11, 2195-2204.
43. Gottfried E, Kreutz M, and Mackensen A (2012). Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol 22, 335-341.
44. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, and Chiarugi P (2012). Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 72, 5130-5140.
45. Gao W, Zeng J, Li H, Yu J, Chan W, Ho WK, and Wong T-S (2012). mTOR pathway and mTOR inhibitors in head and neck cancer. Otolaryngology 2012, 1-7.
46. Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, Mills GB, and Kondo S (2007). Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26, 1840-1851.
47. Kim KW, Hwang M, Moretti L, Jaboin JJ, Cha YI, and Lu B (2008). Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 4, 659-668.
48. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, and Lu B (2006). Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66, 10040-10047.
49. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, and Kroemer G (2011). Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883.
50. Ren J-H, He W-S, Nong L, Zhu Q-Y, Hu K, Zhang R-G, Huang L-L, Zhu F, and Wu G (2010). Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 25, 75-80.
51. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, and Kroemer G (2008). Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 20, 504-511.
52. Frisch M, Biggar RJ, and Goedert JJ (2000). Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92, 1500-1510.
53. Chaturvedi AK, Madeleine MM, Biggar RJ, and Engels E (2009). Risk of human papillomavirus-associated cancers among persons with AIDS. J NatlCancer Inst 101, 1120-1130.
54. Hinten F, Meeuwis KAP, Van Rossum MM, and De Hullu JA (2012). HPVrelated (pre)malignancies of the female anogenital tract in renal transplant recipients. Crit Rev Oncol Hematol 84, 161-180.
55. Aubin F, Martin M, Puzenat E, Magy-Bertrand N, Segondy M, Riethmuller D, and Wendling D (2011). Genital human papillomavirus infection in patients with autoimmune inflammatory diseases. Joint Bone Spine 78, 460-465.